Skip to main content
Erschienen in: The Journal of Behavioral Health Services & Research 3/2017

09.05.2017

Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data

verfasst von: Traci R. Rieckmann, PhD, Nicholas Gideonse, MD, Amanda Risser, MD, MPH, Jennifer E. DeVoe, MD, Amanda J. Abraham, PhD

Erschienen in: The Journal of Behavioral Health Services & Research | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Research has examined the safety, efficacy, feasibility, and cost-effectiveness of buprenorphine for the treatment of opioid dependence, but few studies have examined patient and provider experiences, especially in community health centers. Using de-identified electronic health record system (EHRS) data from 70 OCHIN community health centers (n = 1825), this cross-sectional analysis compared the demographics, comorbidities, and service utilization of patients receiving buprenorphine to those not receiving medication-assisted treatment (MAT). Compared to non-MAT patients, buprenorphine patients were younger and less likely to be Hispanic or live in poverty. Buprenorphine patients were less likely to have Medicaid insurance coverage, more likely to self-pay, and have private insurance coverage. Buprenorphine patients were less likely to have problem medical comorbidities or be coprescribed high-risk medications. It is important for providers, clinic administrators, and patients to understand the clinical application of medications for opioid dependence to ensure safe and effective care within safety net clinics.
Literatur
1.
Zurück zum Zitat Center for Disease Control. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at http://wonder.cdc.gov . Center for Disease Control. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at http://wonder.cdc.gov .
2.
Zurück zum Zitat Substance Abuse and Mental Health Services Association. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15–4927, NSDUH Series H-50), Rockville, MD, 2014. Substance Abuse and Mental Health Services Association. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15–4927, NSDUH Series H-50), Rockville, MD, 2014.
4.
Zurück zum Zitat Shortell SM, Casalino LP, Fisher ES. How the center for Medicare and Medicaid innovation should test accountable care organizations. Health Aff 2010;29(7): 1293–8.CrossRef Shortell SM, Casalino LP, Fisher ES. How the center for Medicare and Medicaid innovation should test accountable care organizations. Health Aff 2010;29(7): 1293–8.CrossRef
5.
Zurück zum Zitat Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004;13 Suppl 1:S42–66.CrossRefPubMedPubMedCentral Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004;13 Suppl 1:S42–66.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatr 1999 Nov;156(11):1758–64.PubMed Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatr 1999 Nov;156(11):1758–64.PubMed
7.
Zurück zum Zitat Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: What to expect. Fam Med 2008;40(7):500–6.PubMedPubMedCentral Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: What to expect. Fam Med 2008;40(7):500–6.PubMedPubMedCentral
8.
Zurück zum Zitat Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2): 231–41.CrossRefPubMed Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2): 231–41.CrossRefPubMed
9.
Zurück zum Zitat Johnson R, Chutuape M, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343(18): 1290–7.CrossRefPubMed Johnson R, Chutuape M, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343(18): 1290–7.CrossRefPubMed
10.
Zurück zum Zitat Ling W, Charuvastra C, Collins J, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998;93(4): 475–86.CrossRefPubMed Ling W, Charuvastra C, Collins J, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998;93(4): 475–86.CrossRefPubMed
11.
Zurück zum Zitat Monti P, Rohsenow D, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25(11): 1634–47.CrossRefPubMed Monti P, Rohsenow D, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25(11): 1634–47.CrossRefPubMed
13.
Zurück zum Zitat Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry 2011;68(12): 1238–46.CrossRefPubMedPubMedCentral Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry 2011;68(12): 1238–46.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 2005;181(4): 664–75.CrossRefPubMedPubMedCentral Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 2005;181(4): 664–75.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine in opioid-related disorders. Can Fam Physician 2012;58(1):37–41.PubMedPubMedCentral Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine in opioid-related disorders. Can Fam Physician 2012;58(1):37–41.PubMedPubMedCentral
16.
Zurück zum Zitat Ling W, Jacobs P, Hillhouse M, et al. From research to real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abus Treat 2010;38(S1): S53–60.CrossRef Ling W, Jacobs P, Hillhouse M, et al. From research to real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abus Treat 2010;38(S1): S53–60.CrossRef
17.
Zurück zum Zitat Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006;43(S4): S173–7.CrossRefPubMed Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006;43(S4): S173–7.CrossRefPubMed
18.
Zurück zum Zitat Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011;57(3): 281–9.PubMedPubMedCentral Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011;57(3): 281–9.PubMedPubMedCentral
19.
Zurück zum Zitat Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs 2010 Sep;42(3):339–46.CrossRefPubMedPubMedCentral Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs 2010 Sep;42(3):339–46.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abus Treat 2010;39(4): 340–52.CrossRef Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abus Treat 2010;39(4): 340–52.CrossRef
21.
Zurück zum Zitat Ridge G, Gossop M, Lintzeris N. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abus Treat 2009;37(1): 95–100.CrossRef Ridge G, Gossop M, Lintzeris N. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abus Treat 2009;37(1): 95–100.CrossRef
22.
Zurück zum Zitat Polsky D, Glick HA, Yang J, et al. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction 2010;105(9): 1616–24.CrossRefPubMedPubMedCentral Polsky D, Glick HA, Yang J, et al. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction 2010;105(9): 1616–24.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat American Society of Addiction Medicine. 2016 The National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD American Society of Addiction Medicine. 2016 The National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD
24.
Zurück zum Zitat Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP). Series 40, DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP). Series 40, DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
25.
Zurück zum Zitat Centers for Disease Control and Prevention. Planning and Implementing Screening and Brief Intervention for Risky Alcohol Use: A Step-by-Step Guide for Primary Care Practices. Atlanta, Georgia: Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 2014. Centers for Disease Control and Prevention. Planning and Implementing Screening and Brief Intervention for Risky Alcohol Use: A Step-by-Step Guide for Primary Care Practices. Atlanta, Georgia: Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 2014.
26.
Zurück zum Zitat Baldini A, Von Korff M, Lin EH. 2012 A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. The Primary Care Companion for CNS Disorders. 14(3) Baldini A, Von Korff M, Lin EH. 2012 A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. The Primary Care Companion for CNS Disorders. 14(3)
27.
Zurück zum Zitat Costenbader EC, Zule WA, Coomes CM. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for Hepatitis C infection. Drug Alcohol Depend 2007;89(2–3): 251–58.CrossRefPubMedPubMedCentral Costenbader EC, Zule WA, Coomes CM. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for Hepatitis C infection. Drug Alcohol Depend 2007;89(2–3): 251–58.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2010;54(2): 152–59.PubMedPubMedCentral Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2010;54(2): 152–59.PubMedPubMedCentral
31.
Zurück zum Zitat Rowe TA, Jacapraro JS, Rastegar DA. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems. Addiction Science and Clinical Practice 2012;7(22): 1–5. Rowe TA, Jacapraro JS, Rastegar DA. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems. Addiction Science and Clinical Practice 2012;7(22): 1–5.
33.
Zurück zum Zitat Grella CE, Karno MP, Warda US, et al. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav 2009;34(6–7): 498–504.CrossRefPubMedPubMedCentral Grella CE, Karno MP, Warda US, et al. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav 2009;34(6–7): 498–504.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Bogdanowicz KM, Stewart R, Broadbent M, et al. Double trouble: Psychiatric comorbidity and opioid addiction-all-cause and cause-specific mortality. Drug Alcohol Depend 2015; 148: 85–92.CrossRefPubMed Bogdanowicz KM, Stewart R, Broadbent M, et al. Double trouble: Psychiatric comorbidity and opioid addiction-all-cause and cause-specific mortality. Drug Alcohol Depend 2015; 148: 85–92.CrossRefPubMed
35.
Zurück zum Zitat Mannelli P, Wu L-T, Peindl KS, Gorelick DA. Smoking and Opioid Detoxification: Behavioral Changes and Response to Treatment. Nicotine Tob Res 2013;15(10):1705–1713.CrossRefPubMedPubMedCentral Mannelli P, Wu L-T, Peindl KS, Gorelick DA. Smoking and Opioid Detoxification: Behavioral Changes and Response to Treatment. Nicotine Tob Res 2013;15(10):1705–1713.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Saunders SA, Democratis J, Martin J, et al. Intravenous drug abuse and type 1 diabetes: Financial and healthcare implications. Diabet Med 2004;21(12): 1269–73.CrossRefPubMed Saunders SA, Democratis J, Martin J, et al. Intravenous drug abuse and type 1 diabetes: Financial and healthcare implications. Diabet Med 2004;21(12): 1269–73.CrossRefPubMed
37.
Zurück zum Zitat Stein MD. Medical consequences of substance abuse. The Psychiatry Clinics of North America 1999;22(2): 351–70.CrossRef Stein MD. Medical consequences of substance abuse. The Psychiatry Clinics of North America 1999;22(2): 351–70.CrossRef
38.
Zurück zum Zitat Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012;125(1–2): 8–18.CrossRefPubMedPubMedCentral Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012;125(1–2): 8–18.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat McCance-Katz EF, Sullivan L, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 2010;19(1): 4–16.CrossRefPubMedPubMedCentral McCance-Katz EF, Sullivan L, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 2010;19(1): 4–16.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91(2–3): 269–78.CrossRefPubMedPubMedCentral McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91(2–3): 269–78.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Tai B, McLellan AT. Integrating information on substance use disorders into electronic health record systems. J Subst Abus Treat 2012;43(1): 12–9.CrossRef Tai B, McLellan AT. Integrating information on substance use disorders into electronic health record systems. J Subst Abus Treat 2012;43(1): 12–9.CrossRef
43.
Zurück zum Zitat Fiellin DA, O’Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002;137(8): 688–92.CrossRefPubMed Fiellin DA, O’Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002;137(8): 688–92.CrossRefPubMed
44.
Zurück zum Zitat Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2): 146–50.CrossRefPubMedPubMedCentral Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2): 146–50.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Substance Abuse and Mental Health Services Administration. Alcohol and Drug Services Study (ADSS). The National Treatment System: Outpatient Methadone Facilities. Rockville, MD: Office of Applied Studies, 2004. Substance Abuse and Mental Health Services Administration. Alcohol and Drug Services Study (ADSS). The National Treatment System: Outpatient Methadone Facilities. Rockville, MD: Office of Applied Studies, 2004.
46.
Zurück zum Zitat Shah S, Diwan S. Methadone: Does stigma play a role as a barrier to treatment of chronic pain? Pain Physician 2010;13(3): 289–93.PubMed Shah S, Diwan S. Methadone: Does stigma play a role as a barrier to treatment of chronic pain? Pain Physician 2010;13(3): 289–93.PubMed
47.
Zurück zum Zitat Cunningham C, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med 2006;38(5): 336–40.PubMed Cunningham C, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med 2006;38(5): 336–40.PubMed
48.
Zurück zum Zitat Felice AM, Kouimtsidis C. Improving services offered by GPs to patients with drug addiction. Ment Health Pract 2012;16(1):19–22.CrossRef Felice AM, Kouimtsidis C. Improving services offered by GPs to patients with drug addiction. Ment Health Pract 2012;16(1):19–22.CrossRef
49.
Zurück zum Zitat Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2014. Data on Substance Abuse Treatment Facilities. BHSIS Series S-79, HHS Publication No. (SMA) 16-4963. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2014. Data on Substance Abuse Treatment Facilities. BHSIS Series S-79, HHS Publication No. (SMA) 16-4963. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.
50.
Zurück zum Zitat Substance Abuse and Mental Health Services Administration. The determinations report: a report on the physician waiver program established by the drug addiction treatment act of 2000 (“DATA”). Rockville, MD: U.S. Department of Health and Human Services, 2006. Substance Abuse and Mental Health Services Administration. The determinations report: a report on the physician waiver program established by the drug addiction treatment act of 2000 (“DATA”). Rockville, MD: U.S. Department of Health and Human Services, 2006.
51.
Zurück zum Zitat Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abus Treat 2009;36(3): 244–51.CrossRef Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abus Treat 2009;36(3): 244–51.CrossRef
53.
Zurück zum Zitat Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Administration, 2005. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Administration, 2005.
54.
Zurück zum Zitat Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006;25(4): 91–103.CrossRefPubMed Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006;25(4): 91–103.CrossRefPubMed
55.
Zurück zum Zitat Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007;87(2–3): 164–74.CrossRefPubMed Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007;87(2–3): 164–74.CrossRefPubMed
56.
Zurück zum Zitat Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication assisted treatment. Am J Public Health 2015;105(8): 55–63.CrossRef Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication assisted treatment. Am J Public Health 2015;105(8): 55–63.CrossRef
57.
Zurück zum Zitat Clark RE, Samnaliev M, Baxter JD, et al. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff 2011;30(8): 1425–33.CrossRef Clark RE, Samnaliev M, Baxter JD, et al. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff 2011;30(8): 1425–33.CrossRef
58.
Zurück zum Zitat StataCorp. Release 13: Statistical software [computer program]. College Station, TX: StataCorp LP, 2013. StataCorp. Release 13: Statistical software [computer program]. College Station, TX: StataCorp LP, 2013.
59.
Zurück zum Zitat Sullivan L, Chawarski M, O'Connor P, et al. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79(1): 113–6.CrossRefPubMed Sullivan L, Chawarski M, O'Connor P, et al. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79(1): 113–6.CrossRefPubMed
61.
62.
64.
Zurück zum Zitat Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. Journal of Addiction Medicine and Therapeutic Science 2015;1(2):31–36.CrossRefPubMedPubMedCentral Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. Journal of Addiction Medicine and Therapeutic Science 2015;1(2):31–36.CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015;15:3019.PubMed DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015;15:3019.PubMed
67.
Zurück zum Zitat Druss BG, Von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: Systematic review. Gen Hosp Psychiatry 2006;28(2): 145–53.CrossRefPubMed Druss BG, Von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: Systematic review. Gen Hosp Psychiatry 2006;28(2): 145–53.CrossRefPubMed
Metadaten
Titel
Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data
verfasst von
Traci R. Rieckmann, PhD
Nicholas Gideonse, MD
Amanda Risser, MD, MPH
Jennifer E. DeVoe, MD
Amanda J. Abraham, PhD
Publikationsdatum
09.05.2017
Verlag
Springer US
Erschienen in
The Journal of Behavioral Health Services & Research / Ausgabe 3/2017
Print ISSN: 1094-3412
Elektronische ISSN: 2168-6793
DOI
https://doi.org/10.1007/s11414-017-9553-z

Weitere Artikel der Ausgabe 3/2017

The Journal of Behavioral Health Services & Research 3/2017 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.